Share on StockTwits

Investment analysts at Leerink Swann started coverage on shares of Receptos (NASDAQ:RCPT) in a note issued to investors on Wednesday. The firm set an “outperform” rating and a $60.00 price target on the stock. Leerink Swann’s price objective would indicate a potential upside of 36.30% from the company’s current price.

Shares of Receptos (NASDAQ:RCPT) opened at 44.02 on Wednesday. Receptos has a 52-week low of $15.21 and a 52-week high of $55.00. The stock has a 50-day moving average of $40.05 and a 200-day moving average of $39.12. The company’s market cap is $975.9 million.

Receptos (NASDAQ:RCPT) last announced its earnings results on Tuesday, August 12th. The company reported ($1.04) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.85) by $0.19. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.28 million. On average, analysts predict that Receptos will post $-3.98 earnings per share for the current fiscal year.

RCPT has been the subject of a number of other recent research reports. Analysts at Nomura initiated coverage on shares of Receptos in a research note on Monday, June 30th. They set a “buy” rating and a $63.00 price target on the stock. Separately, analysts at BMO Capital Markets set a $58.00 price target on shares of Receptos in a research note on Tuesday, June 10th. Finally, analysts at Wedbush raised their price target on shares of Receptos to $63.00 in a research note on Tuesday, June 10th. Three investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $55.00.

Receptos, Inc (NASDAQ:RCPT) is a biopharmaceutical company.

Receive News & Ratings for Receptos Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Receptos Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.